6-(cyclohexylmethoxy)-N-(4-(vinylsulfonyl)phenyl)-9H-purin-2-amine

ID: ALA4518287

Cas Number: 2070015-09-5

PubChem CID: 118704754

Product Number: N647339, Order Now?

Max Phase: Preclinical

Molecular Formula: C20H23N5O3S

Molecular Weight: 413.50

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  C=CS(=O)(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1

Standard InChI:  InChI=1S/C20H23N5O3S/c1-2-29(26,27)16-10-8-15(9-11-16)23-20-24-18-17(21-13-22-18)19(25-20)28-12-14-6-4-3-5-7-14/h2,8-11,13-14H,1,3-7,12H2,(H2,21,22,23,24,25)

Standard InChI Key:  KGWSQGUVJUGIPF-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 29 32  0  0  0  0  0  0  0  0999 V2000
    8.7442  -14.1425    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    9.4563  -13.7353    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.1605  -14.1419    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.1605  -14.9614    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.4589  -15.3679    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    8.7442  -14.9666    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.0361  -15.3743    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    8.0361  -16.1938    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.7441  -16.6018    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.7430  -17.4177    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.0346  -17.8296    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.3305  -17.4227    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.3237  -16.6039    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.0346  -18.6491    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    7.3266  -19.0568    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.3266  -19.8762    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.4475  -19.3591    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    8.8552  -18.6491    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   10.9391  -15.2157    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   11.4206  -14.5497    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.9391  -13.8918    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    9.4563  -12.9158    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    8.7441  -12.5040    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.7441  -11.6846    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.0361  -11.2769    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.0361  -10.4575    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.7442  -10.0498    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.4563  -10.4575    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.4563  -11.2769    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  2  0
  3  2  1  0
  4  3  2  0
  5  4  1  0
  6  5  2  0
  1  6  1  0
  6  7  1  0
  7  8  1  0
  9  8  2  0
 10  9  1  0
 11 10  2  0
 12 11  1  0
 13 12  2  0
  8 13  1  0
 11 14  1  0
 14 15  1  0
 15 16  2  0
 14 17  2  0
 14 18  2  0
  4 19  1  0
 20 19  1  0
 21 20  2  0
  3 21  1  0
  2 22  1  0
 22 23  1  0
 23 24  1  0
 25 24  1  0
 26 25  1  0
 27 26  1  0
 28 27  1  0
 29 28  1  0
 24 29  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA4518287

   NU6300

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 413.50

Molecular Weight (Monoisotopic): 413.1522

AlogP: 3.97

#Rotatable Bonds: 7

Polar Surface Area: 109.86

Molecular Species: NEUTRAL

HBA: 7

HBD: 2

#RO5 Violations: ┄

HBA (Lipinski): 8

HBD (Lipinski): 2

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 8.95

CX Basic pKa: 2.34

CX LogP: 3.95

CX LogD: 3.94

Aromatic Rings: 3

Heavy Atoms: 29

QED Weighted: 0.60

Np Likeness Score: -0.82

References

1. Tadesse S, Caldon EC, Tilley W, Wang S..  (2019)  Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update.,  62  (9): [PMID:30543440] [10.1021/acs.jmedchem.8b01469]

2. Sánchez-Martínez C, Lallena MJ, Sanfeliciano SG, de Dios A..  (2019)  Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015-2019).,  29  (20): [PMID:31477350] [10.1016/j.bmcl.2019.126637]

3. Gai C, Harnor SJ, Zhang S, Cano C, Zhuang C, Zhao Q..  (2022)  Advanced approaches of developing targeted covalent drugs.,  13  (12.0): [PMID:36561076] [10.1039/d2md00216g]

4. Xie Z, Hou S, Yang X, Duan Y, Han J, Wang Q, Liao C..  (2022)  Lessons Learned from Past Cyclin-Dependent Kinase Drug Discovery Efforts.,  65  (9.0): [PMID:35235745] [10.1021/acs.jmedchem.1c02190]

Source

Source(1):

• Scientific Literature